CA3242509A1 - Respiratory stimulant parenteral formulations - Google Patents

Respiratory stimulant parenteral formulations

Info

Publication number
CA3242509A1
CA3242509A1 CA3242509A CA3242509A CA3242509A1 CA 3242509 A1 CA3242509 A1 CA 3242509A1 CA 3242509 A CA3242509 A CA 3242509A CA 3242509 A CA3242509 A CA 3242509A CA 3242509 A1 CA3242509 A1 CA 3242509A1
Authority
CA
Canada
Prior art keywords
parenteral formulations
respiratory stimulant
compound
disclosed
stimulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242509A
Other languages
English (en)
French (fr)
Inventor
Joseph V. Pergolizzi
Frank Diana
Jiayi Chen
Devon E. Dodd
Isaac AGYEMANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enalare Therapeutics Inc
Original Assignee
Enalare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enalare Therapeutics Inc filed Critical Enalare Therapeutics Inc
Publication of CA3242509A1 publication Critical patent/CA3242509A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3242509A 2021-12-27 2022-12-23 Respiratory stimulant parenteral formulations Pending CA3242509A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163293985P 2021-12-27 2021-12-27
US63/293,985 2021-12-27
US202263313472P 2022-02-24 2022-02-24
US63/313,472 2022-02-24
PCT/US2022/053935 WO2023129502A1 (en) 2021-12-27 2022-12-23 Respiratory stimulant parenteral formulations

Publications (1)

Publication Number Publication Date
CA3242509A1 true CA3242509A1 (en) 2023-07-06

Family

ID=86992921

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242509A Pending CA3242509A1 (en) 2021-12-27 2022-12-23 Respiratory stimulant parenteral formulations

Country Status (9)

Country Link
US (1) US20230210857A1 (OSRAM)
EP (1) EP4456900A4 (OSRAM)
JP (1) JP2025501169A (OSRAM)
KR (1) KR20240150426A (OSRAM)
AU (1) AU2022426492A1 (OSRAM)
CA (1) CA3242509A1 (OSRAM)
MX (1) MX2024008162A (OSRAM)
TW (1) TW202333732A (OSRAM)
WO (1) WO2023129502A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025523514A (ja) * 2022-06-24 2025-07-23 エナラーレ セラピューティクス インコーポレイテッド 神経性換気不全の処置方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0948358T2 (sl) * 1996-12-24 2012-03-30 Biogen Idec Inc Stabilne tekoče formulacije interferona
EP2646423A4 (en) * 2010-11-29 2014-04-30 Galleon Pharmaceuticals Inc NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR THE TREATMENT OF RESPIRATORY DISORDERS OR DISEASES
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
CN103635179B (zh) * 2011-04-28 2017-12-29 普拉福姆五金器具第二有限公司 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法
SG11201503505QA (en) * 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
GB201502412D0 (en) * 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use

Also Published As

Publication number Publication date
JP2025501169A (ja) 2025-01-17
WO2023129502A1 (en) 2023-07-06
KR20240150426A (ko) 2024-10-15
US20230210857A1 (en) 2023-07-06
EP4456900A1 (en) 2024-11-06
TW202333732A (zh) 2023-09-01
MX2024008162A (es) 2024-09-17
AU2022426492A1 (en) 2024-07-18
EP4456900A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
WO2022125616A8 (en) Dialkyl tryptamines and their therapeutic uses
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
WO2023192602A3 (en) Respiratory stimulant nasal formulations
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
SG10201407538WA (en) Intravenous formulations of neurokinin-1 antagonists
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
NO20051389L (no) Stabilisert farmasoytisk blanding inneholdende basiske hjelpemidler
PH12022553024A1 (en) Inhibitors of nek7 kinase
EP4706683A3 (en) Chewable formulations
WO2023129956A3 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
MX2024014628A (es) Compuesto para inhibir o degradar bcl6 y uso de este en farmacia
SG165162A1 (en) Modified release pharmaceutical formulation
PH12023552774A1 (en) Nek7 inhibitors
MX2024009177A (es) Compuestos y metodos de uso
MY200061A (en) Irak inhibitor and preparation method therefor and use thereof
MX2024008162A (es) Formulaciones parenterales estimulantes respiratorias.
MX2023009052A (es) Compuesto de bifenilo como inmunomodulador, método de preparación para el mismo y uso del mismo.
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
MX2025005209A (es) Compuestos lipídicos y usos de los mismos
GEAP202516737A (en) Compounds for treating cancer
SE0201658D0 (sv) Immediate release pharmaceutical formulation
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
CA2490335A1 (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
BR9708929A (pt) Composto composição farmacêutica e processos para controlar uma infecção bacteriana em um mamífero e para preparar compostos de macrólidos

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213